iRhythm Data Presented at the American Heart Association 2024 Scientific Sessions Reinforce Clinical and Health Economic Value of Zio Long-Term Continuous Monitoring
"Real World Evidence on Health Care Resources Utilization and Economic Burden of Arrhythmias in Patients with Type 2 Diabetes (T2D) and Chronic Obstructive Pulmonary Disease (COPD)” These data, presented at the American Heart Association’s 2024 Scientific Sessions, are part of iRhythm’s comprehensive clinical evidence program, encompassing over 100 original research publications2 and insights from over 1.5 billion hours of curated heartbeat data.2 This ongoing commitment reflects iRhythm's dedication to expanding clinical evidence that supports improved patient outcomes.iRhythm’s AHA Presentations Details: "Digital engagement with a patient smartphone app and text messaging is associated with increased compliance in patients undergoing long-term continuous ambulatory cardiac monitoring” study This study sought to determine if two optional direct-to-patient digital interventions, the MyZio smartphone app and short messages services (SMS) text notifications, impacts patient compliance (i.e., activation, wear, and device return within 45 days) in patients who self-applied and activated a Zio 14-day patch-based long-term continuous ambulatory monitoring (LTCM) device shipped directly to their home.
"Digital Engagement With a Patient Smartphone App and Text Messaging is Associated with Increased Compliance in Patients Undergoing Long-Term Continuous Ambulatory Cardiac Monitoring”"Feasibility of Point-Of-Wear Patient Satisfaction Surveys to Validate Patient-Centered Product Enhancements: Results From Over 300,000 Patients for Long-Term Ambulatory Cardiac Monitoring” Evaluating Sleep and Activity Arrhythmia Patterns Using LTCM Two studies assessed the feasibility and clinical utility of using the Zio system to monitor arrhythmias in relation to sleep and activity patterns.1 Analyzing and classifying arrhythmia occurrences during sleep and physical exertion provides insights that may inform more personalized arrhythmia management.
The five studies presented by iRhythm span three focus areas for long-term continuous monitoring (LTCM): patient engagement and satisfaction through digital tools and patient-centered product enhancements, evaluating arrhythmia patterns during periods of sleep and activity, and assessing the potential healthcare resource and economic impact of early arrhythmia detection in patients with type 2 diabetes and chronic obstructive pulmonary disease (COPD).
The story "iRhythm Data Presented at the American Heart Association 2024 Scientific Sessions Reinforce Clinical and Health Economic Value of Zio Long-Term Continuous Monitoring" has 1743 words across 58 sentences, which will take approximately 8 - 15 minutes for the average person to read.
Which news outlet covered this story?
The story "iRhythm Data Presented at the American Heart Association 2024 Scientific Sessions Reinforce Clinical and Health Economic Value of Zio Long-Term Continuous Monitoring" was covered 1 weeks ago by GlobeNewswire, a news publisher based in China.
How trustworthy is 'GlobeNewswire' news outlet?
GlobeNewswire is a fully independent (privately-owned) news outlet established in 1998 that covers mostly technology news.
The outlet is headquartered in China and publishes an average of 30 news stories per day.
It's most recent story was published 8 hours ago.
What do people currently think of this news story?
The sentiment for this story is currently Negative, indicating that people regard this as "bad news".
How do I report this news for inaccuracy?
You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.
